Ironwood Pharmaceuticals Inc has a consensus price target of $17.5, established from looking at the 10 latest analyst ratings. The last 3 analyst ratings were released from Wells Fargo, Piper Sandler, and Craig-Hallum on March 1, 2024, February 16, 2024, and January 17, 2024. With an average price target of $18.67 between Wells Fargo, Piper Sandler, and Craig-Hallum, there's an implied 131.02% upside for Ironwood Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/01/2024 | IRWD | Buy Now | Ironwood Pharmaceuticals | $8.08 | 73.27% | Wells Fargo | Mohit Bansal | $20 → $14 | Maintains | Overweight | Get Alert |
02/16/2024 | IRWD | Buy Now | Ironwood Pharmaceuticals | $8.08 | 159.9% | Piper Sandler | David Amsellem | $20 → $21 | Maintains | Overweight | Get Alert |
01/17/2024 | IRWD | Buy Now | Ironwood Pharmaceuticals | $8.08 | 159.9% | Craig-Hallum | Chase Knickerbocker | → $21 | Initiates | → Buy | Get Alert |
12/14/2023 | IRWD | Buy Now | Ironwood Pharmaceuticals | $8.08 | 147.52% | Wells Fargo | Mohit Bansal | → $20 | Initiates | → Overweight | Get Alert |
09/28/2023 | IRWD | Buy Now | Ironwood Pharmaceuticals | $8.08 | 172.28% | JMP Securities | Jason Butler | → $22 | Initiates | → Market Outperform | Get Alert |
05/23/2023 | IRWD | Buy Now | Ironwood Pharmaceuticals | $8.08 | 135.15% | Piper Sandler | David Amsellem | $16 → $19 | Maintains | Overweight | Get Alert |
08/16/2022 | IRWD | Buy Now | Ironwood Pharmaceuticals | $8.08 | 60.89% | Wells Fargo | Jacob Hughes | $12 → $13 | Maintains | Equal-Weight | Get Alert |
04/22/2022 | IRWD | Buy Now | Ironwood Pharmaceuticals | $8.08 | 98.02% | Piper Sandler | David Amsellem | → $16 | Initiates | → Overweight | Get Alert |
10/12/2021 | IRWD | Buy Now | Ironwood Pharmaceuticals | $8.08 | 73.27% | Morgan Stanley | David Lebowitz | — | Maintains | Equal-Weight | Get Alert |
07/16/2021 | IRWD | Buy Now | Ironwood Pharmaceuticals | $8.08 | 48.51% | Morgan Stanley | David Lebowitz | — | Maintains | Equal-Weight | Get Alert |
The latest price target for Ironwood Pharmaceuticals (NASDAQ: IRWD) was reported by Wells Fargo on March 1, 2024. The analyst firm set a price target for $14.00 expecting IRWD to rise to within 12 months (a possible 73.27% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Ironwood Pharmaceuticals (NASDAQ: IRWD) was provided by Wells Fargo, and Ironwood Pharmaceuticals maintained their overweight rating.
There is no last upgrade for Ironwood Pharmaceuticals.
There is no last downgrade for Ironwood Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ironwood Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ironwood Pharmaceuticals was filed on March 1, 2024 so you should expect the next rating to be made available sometime around March 1, 2025.
While ratings are subjective and will change, the latest Ironwood Pharmaceuticals (IRWD) rating was a maintained with a price target of $20.00 to $14.00. The current price Ironwood Pharmaceuticals (IRWD) is trading at is $8.08, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.